Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kymab names Groendahl CEO, Chiswell as chair

This article was originally published in Scrip

Executive Summary

Biopharmaceutical firm Kymab, which develops fully human monoclonal antibodies, has named Dr Christian Groendahl and Dr David Chiswell chief executive officer and chair of the board, respectively. Dr Groendahl joins the Cambridge, UK-based firm from Zealand Pharma where he was chief scientific officer. Meanwhile Dr Chiswell has previously been chair of a number of biotechnology companies – including Nabriva Therapeutics, Sosei, and Daniolabs – and is currently non-executive chair of Albireo Pharma and a director of Nabriva Therapeutics. He joined the Kymab board in 2012. Both appointments are effective from 16 September 2013.

You may also be interested in...



VC View: Deal-Making During A Pandemic And 2021 Expectations

In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.

Snapshot: August Highlights

A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.

‘Translators’ Will Form The Next Generation Of Biopharma Leaders

Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.

Related Companies

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel